Lupin Secures Tentative FDA Approval for Sugammadex Injection

Lupin Limited has secured tentative approval from the U.S. FDA for its Sugammadex Injection in two dosage strengths, marking a significant regulatory milestone for the company.

The product is bioequivalent to Merck's Bridion Injection and is indicated for reversing neuromuscular blockade in adults and pediatric patients aged 2 years and older during surgical procedures.

This approval represents an important addition to Lupin's pharmaceutical portfolio in the U.S. market, where it will compete with Merck's dominant product.